New Therapies in Advanced Cutaneous Malignancies

Piotr Rutkowski is Professor of Surgical Oncology at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Dr Rutkowski is the current Head of the Department of Soft Tissue/Bone Sarcoma and Melanoma, the Plenipotentiary Director of Institute for Clinical Trials at the Maria Sklodowska-Curie Institute - Oncology Center as well as the VicePresident of Scientific Council of Maria Sklodowska-Curie Institute - Oncology Center. He has participated in several investigator-driven trials in melanoma and sarcoma. He is also Coordinator of the Polish Clinical GIST Registry, and a reviewer for several international scientific journals, as well as a member of the Editorial Board of Annals of Surgical Oncology and European Journal of Surgical Oncology. Dr Rutkowski is an active member of the EORT^14000), and is co-author of national and international recommendations for sarcoma and melanoma. He is working very closely with national patient advocacy groups for GIST/sarcoma and melanoma and is Chairman of the Melanoma Academy in Poland. Chair of Task Group of Ministry of Health, Poland for National Oncological Strategy.

Part 1. Pathological, molecular and immunological background of Cutaneous Malignancies.- Pathology of Melanoma and Skin Carcinomas.- Molecular Landscape Profile of Melanoma.- Molecular Landscape of Skin Carcinomas.- Immunological Features of Melanoma.- Part 2. Targeted Therapies in Skin Cancers.- Dabrafenib and Trametinib.- Vemurafenib and Cobimetinib.- Encorafenib and Binimetinib.- Vismodegib.- Sonidegib.- Part 3. Immunological Strategies in Advanced Melanoma.- Ipilimumab.- Nivolumab.- Pembrolizumab.- Talimogene Leharparepvec.- Part 4. Future of Melanoma Immunotherapy.- Perspectives of Immunotherapy in Advanced Melanoma Combinations and Sequencing.- Part 5. Immunological Therapies in Advanced Skin Carcinomas.- Avelumab.- Cemiplimab.- Perspectives of Immunotherapy in Non-Melanoma Skin Cancers.- Part 6. Mechanism of Resistance to Therapy.- Mechanisms of Resistance to Targeted Therapies in Skin Cancer.- Mechanisms of Resistance to Immunotherapy.- Part 7. Perioperative Therapy of Melanoma.- Neoadjuvant and Adjuvant Therapy in Melanoma.- Part 8. Special Techniques and Populations.- Adoptive Cell Therapy Immunological Therapies in Special Populations: HIV, Hepatitis and Organ Transplantation.- Conclusions.